These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23251918)

  • 1. Genmab signs cancer deal with Janssen.
    Tung J
    Bioanalysis; 2012 Oct; 4(19):2327. PubMed ID: 23251918
    [No Abstract]   [Full Text] [Related]  

  • 2. Deal watch: J&J and Genmab deal to push forward CD38 as a blood cancer target.
    Flemming A
    Nat Rev Drug Discov; 2012 Nov; 11(11):822. PubMed ID: 23123932
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?
    Oliva S; Palumbo A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1295-300. PubMed ID: 27351375
    [No Abstract]   [Full Text] [Related]  

  • 4. Companies wager high on CD38-targeting drugs for blood cancer.
    Hersher R
    Nat Med; 2012 Oct; 18(10):1446. PubMed ID: 23042333
    [No Abstract]   [Full Text] [Related]  

  • 5. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic monoclonal antibodies against multiple myeloma].
    Kuroda J
    Nihon Rinsho; 2015 Jan; 73(1):119-23. PubMed ID: 25626316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma yields to CD38 inhibitors.
    Cancer Discov; 2015 Mar; 5(3):OF5. PubMed ID: 25596281
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
    Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
    N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cancer drug shows promise, at a price that many can't pay.
    Berenson A
    N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
    [No Abstract]   [Full Text] [Related]  

  • 10. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Just mad about mAbs.
    Jacobs T
    Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
    [No Abstract]   [Full Text] [Related]  

  • 12. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 14. Battle over eye medicine gives drugmaker a dose of reality.
    Hayden EC
    Nat Med; 2008 Feb; 14(2):108. PubMed ID: 18256604
    [No Abstract]   [Full Text] [Related]  

  • 15. How drug's rebirth as treatment for cancer fueled price rises.
    Anand G
    Wall St J (East Ed); 2004 Nov; ():A1, A18. PubMed ID: 15586943
    [No Abstract]   [Full Text] [Related]  

  • 16. Next-generation monoclonals less profitable than trailblazers?
    Mitchell P
    Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
    [No Abstract]   [Full Text] [Related]  

  • 17. When the price is right.
    Nat Biotechnol; 2006 May; 24(5):473. PubMed ID: 16680108
    [No Abstract]   [Full Text] [Related]  

  • 18. Can 'double blockbuster' strengthen Amgen's backbone?
    Sheridan C
    Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
    [No Abstract]   [Full Text] [Related]  

  • 19. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 20. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
    Kuroda J; Nagoshi H; Shimura Y; Taniwaki M
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1081-8. PubMed ID: 24053207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.